A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma
Shuichiro Iwasaki(Kitasato University), Wasaburo Koizumi(Kitasato University), Takahide Nakazawa(Kitasato University Hospital), Akitaka Shibuya, Takeru Nabeta(Kitasato University), Naohisa Wada(Kitasato University), Itaru Sanoyama(Kitasato University), Haruki Uojima(National Center for Global Health and Medicine), Hisashi Hidaka(Kitasato University), Kousuke Kubota(Kitasato University), Miho Hashimura(Kitasato University)
Cited by 14
Related Papers
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586
Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase.
|Journal of Biological Chemistry|1987|513
MAPKAP kinase‐2; a novel protein kinase activated by mitogen‐activated protein kinase.
|The EMBO Journal|1992|481